| Micro-channel |
 |
|
|
|
|
|
| |
| Chinese medicine injection is afraid of losing its hot selling aura! Antithrombotic pattern rearrangement |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-8-11 8:44:42 Number Browse：878 |
| |
Medical website August 10
Chinese medicine injection and auxiliary medicine
Watch: unload the hospital sales front halo
In 2016, the hospital market of 95 common TCM injections was about 16.2 billion yuan. Provinces since 2016 focus on drug monitoring directory list of TCM injections occupy all more than ninety percent share of the TCM injections, traditional Chinese medicine injection, and the total amount of the top ten hospitals the product into the focus of drug monitoring directory.
Clinical use of TCM injections in 2017 further limits: with medical insurance directory published in February 2017, TCM injections coverage limit strictly, one product is limited to qingrejiedu, heart head blood-vessel, anticancer class.
And the antithrombotic effect of traditional Chinese medicine injections prior to the release of restrictions in health care most is the hospital market sales of the top products, ShuXieTong injection, blood shu ning injection, refreshing static injection, Dan red injection and injection with salvia miltiorrhiza polyphenols acid salt in traditional Chinese medicine injection, and the total amount of the top ten hospitals. As shown in table 1, the increased coverage of health insurance is mainly restricted by channels, and the sales volume is expected to be affected.
Western medicine, nerve protection, repair, and nutrition, such as cerebrovascular KuoZhangJi injection in antithrombotic therapy auxiliary status of drug is restricted, as shown in table 2, have different indications and use time limit. With the further advancement of clinical pathway, the clinical use of such drugs is becoming increasingly limited.
Incremental direct thrombin inhibitor and direct Xa factor inhibitor
Watch out: the new health care products deserve attention
However, traditional Chinese medicine injections and the limited medical insurance are expected to provide some room for growth in the treatment of antithrombotic drugs.
2017 medicare catalog will resist antithrombotic drugs into vitamin K antagonists, heparin and platelet aggregation inhibitor, except the heparin, enzymes, direct thrombin inhibitors, direct factor Xa inhibitors thrombosis and other antibacterial drugs, 7 classes. The new health insurance products include itiptibufen, indobufen, agaroban, dabiega, alpazam, sodium sulfonda, and sulfonate.
As shown in table 3, the market size of heparin sample hospital is more than 50 million yuan. Platelet aggregation inhibitor (except heparin) is a solo by clopidogrel. The direct Xa factor inhibitor, which was only available for health care in 2009, is expected to grow significantly in 2017, with the number of people entering the health care program in the city of alpazaban, sulfonda and sulfonate. Direct thrombin inhibitors first have a product in the health care directory.
Imitation of clopidogrel, rivastaban, apalaban and tigeralot
Banana bonus: the big four products copy the heat
After 2016, formed the antithrombotic class medicine in clinical drug less, domestic enterprises only the Chinese people's liberation army military academy of medical sciences institute of radiation and radiation medicine three advantageous and ze biological technology co., LTD. And Beijing to jointly develop new leech injection with restructuring element start Ⅰ phase of clinical trial, the indications for lower extremity deep vein thrombosis. Novartis's recombinant hirudin product, desirudin, has been listed abroad but has no sales at home.
Generic drugs, although the chemical medicine generics consistency evaluation of project quality requirements more and more high, the project cost also increased significantly with the standard of ascension, but the drug manufacturers against thrombus class generic declaration is still hot, mainly concentrated in the clopidogrel bisulfate tablet and the laval shaaban, pp shaaban pills and for Greg los piece of four products. Astrazeneca's for Greg los plates though not released in February 2017, health insurance directory list, but at 8.45 yuan (90 mg/tablet) to pay for health care standards into the medical insurance directory directory, be incorporated into the national basic medical insurance, inductrial injury insurance and maternity insurance drug catalogue b range.
Summary < < <
Traditional Chinese medicine injections and adjuvant drugs are expected to decline after the health insurance restrictions, thus creating a space for the growth of therapeutic drugs. According to the present situation of the four anti-thrombotic drug generics, the production enterprises that have relied on single traditional Chinese medicine injection and auxiliary medicine support performance have not begun to compete for the hot generic drugs.
|
| |
Previous article：Shandong province 6 city sanjia hospital "one ticket system", time decided!
Next article：In the field of drug circulation, the second half of the "serious play" is staged, and the focus of enterprises should be seen from the high frequency defect item
|
| |
|
|
